11 reports of this reaction
3.2% of all METHENAMINE, SODIUM SALICYLATE reports
#3 most reported adverse reaction
MALAISE is the #3 most commonly reported adverse reaction for METHENAMINE, SODIUM SALICYLATE, manufactured by Aurobindo Pharma Limited. There are 11 FDA adverse event reports linking METHENAMINE, SODIUM SALICYLATE to MALAISE. This represents approximately 3.2% of all 348 adverse event reports for this drug.
Patients taking METHENAMINE, SODIUM SALICYLATE who experience malaise should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALAISE is moderately reported among METHENAMINE, SODIUM SALICYLATE users, representing a notable but not dominant share of adverse events.
In addition to malaise, the following adverse reactions have been reported for METHENAMINE, SODIUM SALICYLATE:
The following drugs have also been linked to malaise in FDA adverse event reports:
MALAISE has been reported as an adverse event in 11 FDA reports for METHENAMINE, SODIUM SALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALAISE accounts for approximately 3.2% of all adverse event reports for METHENAMINE, SODIUM SALICYLATE, making it one of the most commonly reported side effect.
If you experience malaise while taking METHENAMINE, SODIUM SALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.